Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications

  • Seyedmojtaba SeyedmousaviEmail author
  • Paul E. VerweijEmail author
Reference work entry


The medical triazoles, itraconazole, voriconazole, and posaconazole, are the most widely used drugs for the management of infections caused by the saprophytic mold Aspergillus fumigatus. However, acquired azole resistance in A. fumigatus is an emerging problem that compromises the clinical efficacy of azole antifungals. Several mutations in the cyp51A gene of A. fumigatus affect the activity of all mold-active antifungal azoles. These mutations result in the complete loss of activity of a specific azole and are commonly associated with cross-resistance to other azoles. While azole resistance may emerge during antifungal therapy of individual azole-treated patients, selection of resistance can also occur in the environment. The selection for azole resistance within the environment poses an emerging global threat as mutations associated with environmental resistance have now been detected with increasing frequency in multiple European countries, Asia, the Middle East, and Africa.


Aspergillus fumigatus Azole- resistance Epidemiology Clinical implications 


  1. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL (2009) Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother 53:4514–4517PubMedPubMedCentralCrossRefGoogle Scholar
  2. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Moller N, Khan H, Melchers WJ, Verweij PE (2010) Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5, e10080PubMedPubMedCentralCrossRefGoogle Scholar
  3. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility T (2012a) EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 18:E248–E250PubMedCrossRefGoogle Scholar
  4. Arendrup MC, Jensen RH, Grif K, Skov M, Pressler T, Johansen HK, Lass-Florl C (2012b) In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis 206:981–985PubMedCrossRefGoogle Scholar
  5. Arne P, Thierry S, Wang D, Deville M, Le Loc’h G, Desoutter A, Femenia F, Nieguitsila A, Huang W, Chermette R, Guillot J (2011) Aspergillus fumigatus in Poultry. Int J Microbiol 2011:746356PubMedPubMedCentralCrossRefGoogle Scholar
  6. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG (2010) Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50:1559–1567PubMedPubMedCentralCrossRefGoogle Scholar
  7. Balajee SA (2009) Aspergillus terreus complex. Med Mycol 47(Suppl 1):S42–S46PubMedCrossRefGoogle Scholar
  8. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv113Google Scholar
  9. Buied A, Moore CB, Denning DW, Bowyer P (2013) High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J Antimicrob Chemother 68:512–514PubMedCrossRefGoogle Scholar
  10. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, Honore I, Dupouy-Camet J, Dusser D, Klaassen CH, Meis JF, Hubert D, Paugam A (2012) High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 56:869–874PubMedPubMedCentralCrossRefGoogle Scholar
  11. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ (2012a) Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56:10–16PubMedPubMedCentralCrossRefGoogle Scholar
  12. Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, Huynen MA, Verweij PE, Melchers WJ (2012b) Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One 7, e50034PubMedPubMedCentralCrossRefGoogle Scholar
  13. Camps SM, Rijs AJ, Klaassen CH, Meis JF, O’Gorman CM, Dyer PS, Melchers WJ, Verweij PE (2012c) Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 50:2674–2680PubMedPubMedCentralCrossRefGoogle Scholar
  14. Chen J, Li H, Li R, Bu D, Wan Z (2005) Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung Aspergilloma. J Antimicrob Chemother 55:31–37PubMedCrossRefGoogle Scholar
  15. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF (2012a) Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67:362–366PubMedCrossRefGoogle Scholar
  16. Chowdhary A, Kathuria S, Xu J, Sharma C, Sundar G, Singh PK, Gaur SN, Hagen F, Klaassen CH, Meis JF (2012b) Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR(3)(4)/L98H mutations in the cyp51A gene in India. PLoS One 7, e52871PubMedPubMedCentralCrossRefGoogle Scholar
  17. Chowdhary A, Kathuria S, Xu J, Meis JF (2013) Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 9, e1003633PubMedPubMedCentralCrossRefGoogle Scholar
  18. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF (2014) Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 69:555–557PubMedCrossRefGoogle Scholar
  19. Christen Rune Stensvold CR, Jørgensen LN, Arendrup MC (2012) Azole-resistant invasive Aspergillosis: relationship to agriculture. Curr Fungal Infect Rep 6:178–191CrossRefGoogle Scholar
  20. CLSI (2008) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard-Second Edition. CLSI Document. M38-A2., vol 28 no 16. Clinical and laboratory Standards Institute, WaneGoogle Scholar
  21. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359PubMedCrossRefGoogle Scholar
  22. da Silva Ferreira ME, Capellaro JL, dos Reis ME, Malavazi I, Perlin D, Park S, Anderson JB, Colombo AL, Arthington-Skaggs BA, Goldman MH, Goldman GH (2004) In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother 48:4405–4413PubMedPubMedCentralCrossRefGoogle Scholar
  23. de Hoog GS, Guarro J, Gene J, Figueras MJ (2009) Atlas of clinical fungi: the ultimate benchtool for diagnostics, A pilot version of the 3rd edition ed, vol. CD-ROM. Centraalbureau voor Schimmelcultures, KNAW Fungal Biodiversity Centre / Universitat Rovira i Virgili Utrecht/ReusGoogle Scholar
  24. DeLone DR, Goldstein RA, Petermann G, Salamat MS, Miles JM, Knechtle SJ, Brown WD (1999) Disseminated Aspergillosis involving the brain: distribution and imaging characteristics. AJNR Am J Neuroradiol 20:1597–1604PubMedGoogle Scholar
  25. Denning DW (1998) Invasive Aspergillosis. Clin Infect Dis 26:781–803; quiz 804–785PubMedCrossRefGoogle Scholar
  26. Denning DW, Bowyer P (2013) Voriconazole resistance in Aspergillus fumigatus: should we be concerned? Clin Infect Dis 57:521–523PubMedPubMedCentralCrossRefGoogle Scholar
  27. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW (1997) Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 40:401–414PubMedCrossRefGoogle Scholar
  28. Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary Aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872PubMedPubMedCentralCrossRefGoogle Scholar
  29. Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN, Pfaller MA (2009) A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn Microbiol Infect Dis 63:233–236PubMedCrossRefGoogle Scholar
  30. EMA (2012a) European public assessment report (EPAR) for Noxafil, 06/09/2012 ed. European Medicines AgencyGoogle Scholar
  31. EMA (2012b) European public assessment report (EPAR) for Vfend, 04/12/2012 ed. European Medicines AgencyGoogle Scholar
  32. Enserink M (2009) Infectious diseases. Farm fungicides linked to resistance in a human pathogen. Science 326:1173PubMedCrossRefGoogle Scholar
  33. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, Rinaldi MG, Canton E, Turnidge J (2010) Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 48:3251–3257PubMedPubMedCentralCrossRefGoogle Scholar
  34. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility T (2008) EUCAST technical note on fluconazole. Clin Microbiol Infect 14:193–195CrossRefGoogle Scholar
  35. Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P (2013) The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 68:1486–1496PubMedCrossRefGoogle Scholar
  36. Fresenius GW (1863) Beiträge zur Mykologie. Brönner Frankfurt, Frankfurt a. M, pp 81–82Google Scholar
  37. Galimberti R, Kowalczuk A, Hidalgo Parra I, Gonzalez Ramos M, Flores V (1998) Cutaneous Aspergillosis: a report of six cases. Br J Dermatol 139:522–526PubMedCrossRefGoogle Scholar
  38. Gallin JI, Zarember K (2007) Lessons about the pathogenesis and management of Aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc 118:175–185PubMedPubMedCentralGoogle Scholar
  39. Garrett DO, Jochimsen E, Jarvis W (1999) Invasive Aspergillus spp infections in rheumatology patients. J Rheumatol 26:146–149PubMedGoogle Scholar
  40. Gefter WB (1992) The spectrum of pulmonary Aspergillosis. J Thorac Imaging 7:56–74PubMedCrossRefGoogle Scholar
  41. Germaud P, Tuchais E (1995) Allergic bronchopulmonary Aspergillosis treated with itraconazole. Chest 107:883PubMedCrossRefGoogle Scholar
  42. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M (2003) In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 47:3085–3088PubMedPubMedCentralCrossRefGoogle Scholar
  43. Greub G, Bille J (1998) Aspergillus species isolated from clinical specimens: suggested clinical and microbiological criteria to determine significance. Clin Microbiol Infect 4:710–716PubMedCrossRefGoogle Scholar
  44. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E (2008) In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 52:1396–1400PubMedPubMedCentralCrossRefGoogle Scholar
  45. Hamprecht A, Buchheidt D, Vehreschild JJ, Cornely OA, Spiess B, Plum G, Halbsguth TV, Kutsch N, Stippel D, Kahl P, Persigehl T, Steinbach A, Bos B, Hallek M, Vehreschild MJ (2012) Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 17:20262PubMedGoogle Scholar
  46. Heitman J (2011) Microbial pathogens in the fungal kingdom. Fungal Biol Rev 25:48–60PubMedPubMedCentralCrossRefGoogle Scholar
  47. Henriet S, Verweij PE, Holland SM, Warris A (2013) Invasive fungal infections in patients with chronic granulomatous disease. Adv Exp Med Biol 764:27–55PubMedCrossRefGoogle Scholar
  48. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for R, Treatment of C, the Global Aspergillus Study G (2002) Voriconazole versus amphotericin B for primary therapy of invasive Aspergillosis. N Engl J Med 347:408–415PubMedCrossRefGoogle Scholar
  49. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D (2009) Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 47:217–220PubMedCrossRefGoogle Scholar
  50. Hope WW, Cuenca-Estrella M, Lass-Florl C, Arendrup MC, European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility T (2013) EUCAST technical note on voriconazole and Aspergillus spp. Clin Microbiol Infect 19:E278–E280PubMedCrossRefGoogle Scholar
  51. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW (2006) Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 28:450–453PubMedCrossRefGoogle Scholar
  52. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW (2009) Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15:1068–1076PubMedPubMedCentralCrossRefGoogle Scholar
  53. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW (2011) Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 203:1324–1332PubMedPubMedCentralCrossRefGoogle Scholar
  54. Kwon-Chung KJ, Sugui JA (2013) Aspergillus fumigatus–what makes the species a ubiquitous human fungal pathogen? PLoS Pathog 9, e1003743PubMedPubMedCentralCrossRefGoogle Scholar
  55. Lagrou K, Vleeschouwer J, Meersseman W, Dupont L, Verleden GM, Melchers WJG, Verweij PE, Martens J (2008) 3rd Adv. Against Aspergillosis. Miami, p 33Google Scholar
  56. Lass-Florl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL (2009) In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 53:794–795PubMedCrossRefGoogle Scholar
  57. Latge JP (1999) Aspergillus fumigatus and Aspergillosis. Clin Microbiol Rev 12:310–350PubMedPubMedCentralGoogle Scholar
  58. Lepak AJ, Marchillo K, VanHecker J, Andes DR (2013) Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother 57:5438–5447PubMedPubMedCentralCrossRefGoogle Scholar
  59. Liu W, Sun Y, Chen W, Liu W, Wan Z, Bu D, Li R (2012) The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing Aspergillosis. Antimicrob Agents Chemother 56:2598–2603PubMedPubMedCentralCrossRefGoogle Scholar
  60. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA (2011) Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 55:4465–4468PubMedPubMedCentralCrossRefGoogle Scholar
  61. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE (2010a) Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 54:860–865PubMedCrossRefGoogle Scholar
  62. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW (2010b) Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 54:4758–4764PubMedPubMedCentralCrossRefGoogle Scholar
  63. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive Aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170:621–625PubMedCrossRefGoogle Scholar
  64. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL (2004) Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 48:2747–2750PubMedPubMedCentralCrossRefGoogle Scholar
  65. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, Rodriguez-Tudela JL (2007) A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51:1897–1904PubMedPubMedCentralCrossRefGoogle Scholar
  66. Mellado E, De La Camara R, Buendia B, Rodriguez-Tudela JL, Cuenca-Estrella M (2013) Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. Rev Iberoam Micol 30:64–68PubMedCrossRefGoogle Scholar
  67. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L (2008) Current options in antifungal pharmacotherapy. Pharmacotherapy 28:614–645PubMedCrossRefGoogle Scholar
  68. Moore CB, Walls CM, Denning DW (2000) In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 44:441–443PubMedPubMedCentralCrossRefGoogle Scholar
  69. Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, Bretagne S, Miegeville M, Le Pape P (2012) High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 67:1870–1873PubMedCrossRefGoogle Scholar
  70. Mortensen KL, Mellado E, Lass-Florl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC (2010) Environmental study of azole-resistant Aspergillus fumigatus and other Aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 54:4545–4549PubMedPubMedCentralCrossRefGoogle Scholar
  71. Nascimento AM, Goldman GH, Park S, Marras SA, Delmas G, Oza U, Lolans K, Dudley MN, Mann PA, Perlin DS (2003) Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 47:1719–1726PubMedPubMedCentralCrossRefGoogle Scholar
  72. Natesan SK, Lamichchane AK, Swaminathan S, Wu W (2013) Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus. Diagn Microbiol Infect Dis 76:458–463PubMedCrossRefGoogle Scholar
  73. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R (2008) Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47:1176–1184PubMedCrossRefGoogle Scholar
  74. Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013–1025PubMedCrossRefGoogle Scholar
  75. Patterson K, Strek ME (2010) Allergic bronchopulmonary Aspergillosis. Proc Am Thorac Soc 7:237–244PubMedCrossRefGoogle Scholar
  76. Peterson SW (2008) Phylogenetic analysis of Aspergillus species using DNA sequences from four loci. Mycologia 100:205–226PubMedCrossRefGoogle Scholar
  77. Peterson SW, Varga J, Frisvad JC, Samson RA (2008) Phylogeny and subgeneric taxonomy of Aspergillus. Wageningen Academic Publishers, WageningenGoogle Scholar
  78. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Group SP (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46:1032–1037PubMedPubMedCentralCrossRefGoogle Scholar
  79. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ (2008) In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 46:2568–2572PubMedPubMedCentralCrossRefGoogle Scholar
  80. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D (2011) Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol 49:586–590PubMedPubMedCentralCrossRefGoogle Scholar
  81. Pitt JI (1994) The current role of Aspergillus and Penicillium in human and animal health. J Med Vet Mycol 32(Suppl 1):17–32PubMedCrossRefGoogle Scholar
  82. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J (2012) First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob Agents Chemother 56:6060–6061PubMedPubMedCentralCrossRefGoogle Scholar
  83. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB (1997) Chronic necrotizing pulmonary Aspergillosis: approach to management. Chest 112:541–548PubMedCrossRefGoogle Scholar
  84. Segal BH, Romani LR (2009) Invasive Aspergillosis in chronic granulomatous disease. Med Mycol 47(Suppl 1):S282–S290PubMedCrossRefGoogle Scholar
  85. Seyedmousavi S, Hashemi SJ, Zibafar E, Zoll J, Hedayati MT, Mouton JW, Melchers WJ, Verweij PE (2013a) Azole-resistant Aspergillus fumigatus, Iran. Emerg Infect Dis 19:832–834PubMedPubMedCentralCrossRefGoogle Scholar
  86. Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW, Verweij PE (2013b) In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother 57:796–803PubMedPubMedCentralCrossRefGoogle Scholar
  87. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW (2013c) Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Chemother 68:385–393PubMedCrossRefGoogle Scholar
  88. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE (2013d) Pharmacodynamics and dose–response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 57:1866–1871PubMedPubMedCentralCrossRefGoogle Scholar
  89. Seyedmousavi S, Mouton JW, Melchers WJ, Bruggemann RJ, Verweij PE (2014) The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. Drug Resist Updat 17:37–50PubMedCrossRefGoogle Scholar
  90. Seyedmousavi S, Verweij PE, Mouton JW (2015) Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. Expert Rev Anti Infect Ther 13:9–27PubMedCrossRefGoogle Scholar
  91. Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary Aspergillosis including simple Aspergilloma. Eur Respir J 37:865–872PubMedCrossRefGoogle Scholar
  92. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE (2008) Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5, e219PubMedPubMedCentralCrossRefGoogle Scholar
  93. Snelders E, Huis In ’t Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE (2009) Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75:4053–4057PubMedPubMedCentralCrossRefGoogle Scholar
  94. Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, van der Lee HA, Klaassen CH, Melchers WJ, Verweij PE (2012) Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 7, e31801PubMedPubMedCentralCrossRefGoogle Scholar
  95. Soubani AO, Chandrasekar PH (2002) The clinical spectrum of pulmonary Aspergillosis. Chest 121:1988–1999PubMedCrossRefGoogle Scholar
  96. Subcommittee on Antifungal Susceptibility Testing of the EECfAST (2008) EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 14:982–984CrossRefGoogle Scholar
  97. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, Mihara T, Hosogaya N, Takazono T, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Nishino T, Tsukamoto M, Kakeya H, Yamamoto Y, Yanagihara K, Yasuoka A, Tashiro T, Kohno S (2012) Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 56:584–587PubMedPubMedCentralCrossRefGoogle Scholar
  98. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347PubMedCrossRefGoogle Scholar
  99. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, Kuijper EJ, Melchers WJ, Verweij PE (2009) Azole-resistant central nervous system aspergillosis. Clin Infect Dis 48:1111–1113PubMedCrossRefGoogle Scholar
  100. Van Der Linden JW, Warris A, Verweij PE (2011a) Aspergillus species intrinsically resistant to antifungal agents. Med Mycol 49(Suppl 1):S82–S89CrossRefGoogle Scholar
  101. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE (2011b) Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis 17:1846–1854PubMedPubMedCentralCrossRefGoogle Scholar
  102. van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, Chryssanthou E, Mellado E, Kidd SE, Tortorano AM, Dannaoui E, Gaustad P, Baddley JW, Uekötter A, Lass-Flörl C, Klimko N, Moore CB, Denning DW, Pasqualotto AC, Kibbler C, Arikan-Akdagli S, Andes D, Meletiadis J, Naumiuk L, Nucci M, Melchers WJ, Verweij PE (2015) Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis; 21(6):1041-4. doi: 10.3201/eid2106.140717.
  103. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE (2013) Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 57:513–520PubMedCrossRefGoogle Scholar
  104. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE (2007) Aspergillosis–and a misleading sensitivity result. Lancet 370:102PubMedCrossRefGoogle Scholar
  105. Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA (2008) Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell 7:630–638PubMedPubMedCentralCrossRefGoogle Scholar
  106. Vermeulen E, Maertens J, Schoemans H, Lagrou K (2012) Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 17Google Scholar
  107. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF (2002) Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 40:2648–2650PubMedPubMedCentralCrossRefGoogle Scholar
  108. Verweij PE, Mellado E, Melchers WJ (2007) Multiple-triazole-resistant Aspergillosis. N Engl J Med 356:1481–1483PubMedCrossRefGoogle Scholar
  109. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ (2009a) Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 9:789–795PubMedCrossRefGoogle Scholar
  110. Verweij PE, Howard SJ, Melchers WJ, Denning DW (2009b) Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12(6):141–147PubMedCrossRefGoogle Scholar
  111. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of A (2008) Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360PubMedCrossRefGoogle Scholar
  112. Warris A, Weemaes CM, Verweij PE (2002) Multidrug resistance in Aspergillus fumigatus. N Engl J Med 347:2173–2174PubMedCrossRefGoogle Scholar
  113. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT (1970) Aspergillosis. The spectrum of the disease in 98 patients. Medicine 49:147–173PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Medical MicrobiologyRadboud University Medical CenterNijmegenThe Netherlands
  2. 2.Department of Medical Microbiology and Infectious DiseasesErasmus MCRotterdamThe Netherlands

Personalised recommendations